IndustryCompany release

Glaukos corporate deck promotes iDose TR re-administration approval and wider glaucoma pipeline

🇺🇸 GLAUKOS Corp (GKOS) · Fri 06 Nov 2026

The hybrid pharma-device company's presentation highlights January 2026 FDA approval for re-administration of iDose TR, new Phase 3 non-inferiority analysis and earlier-stage iDose follow-on products.

Glaukos has issued a corporate presentation setting out its interventional glaucoma and keratoconus strategy. The company describes itself as a hybrid pharmaceutical-device business. The full text of the deck was not available for this report, so the details below rely on the company's own summary of it.

The presentation highlights iDose TR, a travoprost implant for open-angle glaucoma and ocular hypertension. According to the summary, the US Food and Drug Administration approved the product for re-administration in January 2026. It also cites a new Phase 3 analysis showing non-inferiority to topical timolol at three years.

Beyond the marketed product, the deck points to a next-generation iDose programme. An IND amendment was filed in December 2025, and Phase 3b enrolment has been completed for the product. The company also reports Phase 2a results for iDose TREX and iDose TRIO, both of which are not FDA-approved.

The title of the item also refers to Epioxa and a 14-program pipeline. The material available to VigiEye gave no further detail on either, so they are not described here.

What it means for your team

  • Regulatory teams tracking ophthalmic drug-device combinations should note that re-administration of iDose TR is now FDA-approved, as stated by the company.
  • The Phase 3 three-year non-inferiority analysis against topical timolol is company-reported; it should be checked against full data before being used in comparative assessments.
  • iDose TREX and TRIO remain unapproved and at Phase 2a, so they should not be treated as available options.
  • Market-access teams may wish to watch for further detail on the next-generation iDose product, given the IND amendment and completed Phase 3b enrolment.

Company's press release (SEC filing): GLAUKOS Corp ↗

Article written by VigiEye from the official source (GLAUKOS Corp). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →